Frank Behrens - Concepedia

Author

Frank Behrens

Goethe University Frankfurt ORCID

Also Known As

Behrens, F, Behrens, Frank, F Behrens, F. Behrens, FRANK BEHRENS, Frank Behrens, R. Landewe

307

Publications

7.3K

Citations

H-Index

Concepts

All Affiliations

Goethe University Frankfurt Fraunhofer Institute for Translational Medicine and Pharmacology Fraunhofer Institute for Molecular Biology and Applied Ecology University Hospital Frankfurt Charité - Universitätsmedizin Berlin

About

Frank Behrens is an author at Goethe University Frankfurt specializing in medicine, rheumatology, and psoriatic arthritis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	1.8K
2	Public Health	3	3	524
3	Epidemiology	2	2	509
4	Engineering	1	1	12
5	Family Medicine	1	1	15

Frank Behrens

Publications

5.1K

Citations

H-Index

Page 1

	Year	Citations
Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics Philip J. Mease, Dafna D. Gladman, Kim Papp, Journal of the American Academy of Dermatology RheumatologyRheumatologist-diagnosed Psoriatic ArthritisMedicineRheumatic DiseasesClinical Epidemiology	2013	496
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors Dafna D. Gladman, William F. C. Rigby, Valderílio Feijó Azevedo, New England Journal of Medicine	2017	494
Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double‐blind, randomized, placebo‐controlled clinical trial J. P. Kaltwasser, Peter Nash, Dafna D. Gladman, Arthritis & Rheumatism Rheumatology 20RheumatologyRheumatoid DisorderRheumatic DiseasesPharmacology	2004	411
Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis Ulrike Hüffmeier, Steffen Uebe, Arif B. Ekici, Nature Genetics RheumatologyAutoimmune DiseaseMedicineImmunologyPathology	2010	364
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial Philip J. Mease, Josef S Smolen, Frank Behrens, Annals of the Rheumatic Diseases	2019	280
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis Iain B. McInnes, J. Anderson, Marina Magrey, New England Journal of Medicine	2021	276
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial Iain B. McInnes, Frank Behrens, Philip J. Mease, The Lancet RheumatologyAutoimmune DiseaseMedicineRheumatic DiseasesSystemic Treatment	2020	271
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis Philip J. Mease, Atul Deodhar, Désirée van der Heijde, Annals of the Rheumatic Diseases	2022	188
Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis John Bowes, Ashley Budu‐Aggrey, Ulrike Hüffmeier, Nature Communications	2015	183
MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial Frank Behrens, Paul P. Tak, Mikkel Østergaard, Annals of the Rheumatic Diseases	2014	151

Page 1